Inogen, Inc (INGN) Fair Value & Analysis
Healthcare · US · Market cap $174M
Inogen, Inc
INGN · US
Fair value as of: Jun 25, 2026
From 1 valuation models · updated 4 days ago
Fair value updated Jun 25, 2026 — revised from $31.95 to $3.39 (−89.4%) since Jun 24, 2026. Share price +6.8% over the past month.
Price vs Fair Value (12 months)
12‑month range $5.45 – $8.73 · fair‑value band $2.24 – $4.24 · the $6.76 price screens above the $3.39 fair value. As of Jun 25, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Inogen, Inc (INGN) currently trades at $6.76, while our model-based Fair Value estimate is $3.39 — implying the stock looks roughly 49.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Inogen, Inc generated revenue of $351M at a net margin of -7.1%. Revenue grew 3.4% year over year. It earns a return on equity of -13.1%. The balance sheet holds a net cash position of $86.3M. Fundamentals as of Jun 25, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 25, 2026. TTM = trailing twelve months.
About the company
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It provides Inogen One and Inogen Rove, an ambulatory solution for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Rove 6 concentrator; Inogen Voxi 5, a stationary oxygen concentrator; Aurora for continuous positive airway pressure; CPAP masks; Simeox for airway clearance treatment; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Beverly, Massachusetts.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Inogen, Inc reported revenue of $349M in FY2025 versus $358M in FY2021, a compound −0.7%/yr. Reported net income was −$22.7M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | 1,600 MXN | 1,228 MXN | -23% |
| Stryker Corporation S1YK34 | R$79.21 | R$43.74 | -45% |
| Medtronic plc MDT | $80.25 | $74.40 | -7% |
| Boston Scientific Corporation B1SX34 | R$248.75 | R$221.81 | -11% |
| Edwards Lifesciences Corporation EW | $85.88 | $41.02 | -52% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Inogen, Inc (INGN) undervalued?
What is the fair value of INGN?
What is the quality score of INGN?
What is the revenue of Inogen, Inc (INGN)?
What is the net profit margin of INGN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.